C-X-C motif chemokine receptor 2 (CXCR2) expression is associated with high-grade and advanced prostate cancer. LNCaP-CXCR2+ prostate cancer cells with stable expression of CXCR2 exhibited mesenchymal features and became more aggressive with elevated expression of an ECM oncoprotein EDB-FN as compared to the slow-growing parental cell line, LNCaP. MRMI of EDB-FN with a targeted contrast agent MT218 resulted in significant increase of T1-weighted contrast enhancement in LNCaP-CXCR2+ prostate tumors as compared to the LNCaP tumors in mice. The results suggest that MRMI of EDB-FN has the potential to provide non-invasive active surveillance of low-grade prostate cancer.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords